Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Genetic and pharmacological reduction of CDK14 mitigates synucleinopathy

4 Apr 2024

Abstract excerpt

Parkinson's disease (PD) is a debilitating neurodegenerative disease characterized by the loss of midbrain dopaminergic neurons (DaNs) and the abnormal accumulation of α-Synuclein (α-Syn) protein. Currently, no treatment can slow nor halt the progression of PD. Multiplications and mutations of the α-Syn gene (SNCA) cause PD-associated syndromes and animal models that overexpress α-Syn replicate several features...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Autism Spectrum Disorder Research
Share to Neurological disorders and treatments
Share to Parkinson's Disease Mechanisms and Treatments

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Source

Identifiers

PMID: 38575601
DOI: 10.1038/s41419-024-06534-8

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 10 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Genetic and pharmacological reduction of CDK14 mitigates synucleinopathyPMID 38575601Read ↗

Genetic and pharmacological reduction of CDK14 mitigates α-synuclein pathology in human neurons and in rodent models of Parkinson’s diseaseSemantic proximity Read ↗

Genetic and pharmacological reduction of CDK14 mitigates synucleinopathySemantic proximity Read ↗

A Druggable Genome Screen Identifies Modifiers of α-Synuclein Levels via a Tiered Cross-Species Validation ApproachSemantic proximity Read ↗

CK2 alpha prime and alpha-synuclein pathogenic functional interaction mediates synaptic dysregulation in Huntington’s diseaseSemantic proximity Read ↗

E46K α-Synuclein Mutation Inhibits Cdc42EP2 Expression to Differentially Attenuate Neurite Outgrowth in SK-N-SH CellsSemantic proximity Read ↗

Alpha-Synuclein Phosphomimetic Y39E and S129D Knock-In Mice Show Cytosolic Alpha-Synuclein Localization without Developing Neurodegeneration or Motor DeficitsSemantic proximity Read ↗

Mimicking phosphorylation at serine 87 inhibits the aggregation of human α-synuclein and protects against its toxicity in a rat model of Parkinson's disease.Semantic proximity Read ↗

High Content Screening and Proteomic Analysis Identify a Kinase Inhibitor that rescues pathological phenotypes in a Patient-Derived Model of Parkinson’s DiseaseSemantic proximity Read ↗

High content screening and proteomic analysis identify a kinase inhibitor that rescues pathological phenotypes in a patient-derived model of Parkinson’s diseaseSemantic proximity Read ↗

A novel alpha-synuclein G14R missense variant is associated with atypical neuropathological featuresSemantic proximity Read ↗

Synj1 haploinsufficiency causes dopamine neuron vulnerability and alpha-synuclein accumulation in miceSemantic proximity Read ↗

USP14 regulates pS129 α-synuclein levels and oxidative stress in human SH-SY5Y dopaminergic cellsSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.